CUE vs UBER · rev $9.3M vs P/E 18, rev $52.02B
Cue Biopharma (CUE) versus Uber Technologies Inc (UBER) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Uber Technologies Inc (UBER) is a software - application company listed on NYSE. It is led by Dara Khosrowshahi.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported UBER revenue for 2025-12-31 was $52.02B. Net income was $10.05B. Revenue was up 18.3% from 2024-12-31 to 2025-12-31. UBER currently screens at market cap $144.34B and trailing P/E 17.6.
CUE currently screens at market cap $59.5M. UBER currently screens at market cap $144.34B and trailing P/E 17.6.
Not investment advice. Open the CUE and UBER stock pages for the full models.
Not investment advice.